Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, metabolic syndrome, stroke, metabolic dysfunction-associated steatohepatitis, cardiovascular and renal disorders, among others
There are additional concerns
doi: 10.2174/1381612822666160216151852 121 DingYXiaBHZhangCJZhuoGC
More recently, it has received approval for use as an anti-obesity medication, marketed under the brand name Wegovy
Regulatory Status Disclosure: The FDA declared the semaglutide drug shortage resolved in February 2025 and the tirzepatide drug shortage resolved in October 2024
Helps regulate blood glucose in those with diabetes
US$ 24.70
US$ 26.87
US$ 28.37
US$ 25.52
